NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting
7:16 pm ET 05/20/2010 - PR Newswire
SAN CARLOS, Calif., May 20 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). The oral presentation of NKTR-102 will occur on Sunday, June 6, 2010 at 11:15 am CT. Results will be presented by the lead investigator in the NKTR-102 Phase 2 study, Prof. Dr. Ignace Vergote, Professor and Chairman of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, Belgium.
"We are privileged that the ASCO Scientific Program Committee has accepted our Phase 2 data for NKTR-102 in ovarian cancer for presentation at the Gynecologic Cancer Oral Abstract Session," said Lorianne Masuoka, M.D., Nektar Senior Vice President and Chief Medical Officer. "The notably high objective response rates seen with single-agent NKTR-102 in heavily pretreated patients with platinum-resistant/refractory disease indicate that NKTR-102 holds great potential as a new therapeutic option for even the most difficult-to-treat population within ovarian cancer. Further, the data demonstrate that Nektar's proprietary polymer technology can create greatly improved chemotherapeutic candidates with the potential to address significant unmet medical needs for patients with cancer."
The submitted abstract for NKTR-102, titled "Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer" (Abstract #5013), included response and safety data for 71 patients available as of the date of abstract submission. Consistently high treatment response rates observed with NKTR-102 across all measures in both treatment arms along with a favorable safety profile are summarized in the ASCO abstract, which is available online at www.asco.org and at Nektar's website at the following url: |
